4.6 Review

Emerging potential benefits of modulating NAD+ metabolism in cardiovascular disease

Journal

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpheart.00409.2017

Keywords

cardiovascular diseases; ischemia-reperfusion; nicotinamide adenine dinucleotide; oxidation-reduction (redox)

Funding

  1. National Institutes of Health (NIH) [R01-HL-115955]
  2. American Heart Association Predoctoral Fellowship [17PRE33410450]
  3. NIH-supported Medical Scientist Training Program at the University of Iowa (NIH Grant) [T32-GM007337]

Ask authors/readers for more resources

Nicotinamide adenine dinucleotide (NAD(+)) and related metabolites are central mediators of fuel oxidation and bioenergetics within cardiomyocytes. Additionally, NAD(+) is required for the activity of multifunctional enzymes, including sirtuins and poly(ADP-ribose) polymerases that regulate posttranslational modifications, DNA damage responses, and Ca2+ signaling. Recent research has indicated that NAD(+) participates in a multitude of processes dysregulated in cardiovascular diseases. Therefore, supplementation of NAD(+) precursors, including nicotinamide riboside that boosts or repletes the NAD(+) metabolome, may be cardioprotective. This review examines the molecular physiology and preclinical data with respect to NAD(+) precursors in heart failure-related cardiac remodeling, ischemic-reperfusion injury, and arrhythmias. In addition, alternative NAD(+)-boosting strategies and potential systemic effects of NAD(+) supplementation with implications on cardiovascular health and disease are surveyed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available